Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is trading at $0.90, about ₹86 at today's USD/INR rate, as of 25 Sep 2026, 4:00 PM ET, down 2.48% today. Indian residents can buy Akebia Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$0.89
Today's high
$0.93
52 week low
$0.81
52 week high
$3.20
AKBA opened at $0.92, closed previously at $0.92, and has traded between $0.81 and $3.20 over the past 52 weeks.
About
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Key statistics
Avg. volume
6.17M
Market cap
$240.41M
P/E Ratio
-8.30
Price-to-sales ratio
1.10
Enterprise value
$138.83M
Free cash flow yield
16.74%
Debt-to-equity ratio
2.16
Return on equity
-93.74%
ROIC
-7.08%
Beta
0.23
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$236.20M
Earnings per share
-$0.02
Free cash flow
$67.99M
Net profit margin
-13.54%
Gross margin
79.48%
EBITDA
$21.73M
Revenue growth
47.46%
Similar securities
This is not an investment recommendation
How to buy Akebia Therapeutics from India
Indian residents can buy Akebia Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Akebia Therapeutics and place an order
Find Akebia Therapeutics by name or by its ticker, AKBA, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Akebia Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Akebia Therapeutics position in USD and INR. Akebia Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Akebia Therapeutics from India
Trading and taxes when buying Akebia Therapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneAkebia Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Akebia Therapeutics stock?
Yes. Akebia Therapeutics (AKBA) has been listed on NASDAQ since 2014, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Akebia Therapeutics share cost in rupees?
One Akebia Therapeutics share is $0.90 — about ₹86 at a USD/INR rate of 95.92 on 25 Sep 2026. Both the Akebia Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Akebia Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Akebia Therapeutics?
Yes. One Akebia Therapeutics share is $0.90, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Akebia Therapeutics.
How are gains on Akebia Therapeutics shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Akebia Therapeutics price. Paasa issues a capital-gains statement for your return.
Does Akebia Therapeutics pay a dividend?
No. Akebia Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Akebia Therapeutics from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Akebia Therapeutics shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Akebia Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Akebia Therapeutics holding, its cost and its closing value.
How do I sell Akebia Therapeutics and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.